Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators
Aleksandar Obradović(Columbia University Irving Medical Center), Casey R. Ager(Columbia University Irving Medical Center), Mikko Turunen(Columbia University Irving Medical Center), Thomas R. Nirschl(Johns Hopkins University), Mohsen Khosravi‐Maharlooei(Columbia University Irving Medical Center), Alina C. Iuga(University of North Carolina Health Care), Christopher M. Jackson(Johns Hopkins University), Srinivasan Yegnasubramanian(Johns Hopkins University), Lorenzo Tomassoni(Columbia University Irving Medical Center), Ester Calvo Fernández(Columbia University Irving Medical Center), Patrick McCann(Columbia University Irving Medical Center), Meri Rogava(Columbia University Irving Medical Center), Angelo M. De Marzo(Johns Hopkins University), Christina M. Kochel(Johns Hopkins University), Mohamad E. Allaf(Johns Hopkins University), Trinity J. Bivalacqua(Johns Hopkins University), Michael Lim(Stanford Medicine), Ronald Realubit(Columbia University Irving Medical Center), Charles Karan(Columbia University Irving Medical Center), Charles G. Drake(Johns Hopkins University), Andrea Califano(Johns Hopkins University)
Cited by 56Open Access
Abstract
Related Papers
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
François Ghiringhelli, Cédric Menard, Pierre E. Puig et al.|Cancer Immunology Immunotherapy|2006|1.2k